PTCT Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Ptc Therapeutics, Inc. had $1.7B of revenue in fiscal 2025, up 114.5% on the year before. Over five years, revenue changed +35.4% a year on average.
Last close Β· Oct 23, 2026
$60.59
3.9%Hi! I read Ptc Therapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+114.5%
Yes. Sales grew 114.5% last year.
Does it make a profit?
39.4%
Yes. It keeps 39.4% of every sale as profit.
Does profit turn into cash?
40.6%
Yes. 40.6% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
6 / 8
Mixed. It passes 6 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Ptc Therapeutics, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
October 29, 2026
Thursday Β· in 3 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Jul 28, 2026 | Q2 '26 | Time not announced | 8-K β |
| May 7, 2026 | Q1 '26 | After the market closes | 8-K β |
| Jan 12, 2026 | Q4 '25 | During market hours | 8-K β |
| Nov 4, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 7, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 6, 2025 | Q1 '25 | After the market closes | 8-K β |
| Jan 13, 2025 | Q4 '24 | During market hours | 8-K β |
| Nov 7, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Ptc Therapeutics, Inc. had $1.7B of revenue in fiscal 2025, up 114.5% on the year before. Over five years, revenue changed +35.4% a year on average. Its operating margin was 50.1%, up 87.6Β pts: of every 100 in sales, about 50 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Ptc Therapeutics, Inc. made $683M of net profit in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was $702M in fiscal 2025, 40.6% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Ptc Therapeutics, Inc. has $1.7B more cash than debt.
Cash, debt and the ratios that show how comfortably Ptc Therapeutics, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $773M | $411M | $877M | $1.1B | $1.9B |
| Debt incl. finance leases | $454M | $593M | $304M | $304M | $293M |
| Net debt / EBITDA | β | β | β | β | β1.8x |
| Debt / equity | 300.0x | β | β | β | β |
| Current ratio | 1.9x | 1.7x | 2.0x | 2.4x | 2.3x |
| Quick ratio | 1.8x | 1.7x | 2.0x | 2.3x | 2.3x |
| Total assets | $1.9B | $1.7B | $1.9B | $1.7B | $2.9B |
| Total liabilities | $1.9B | $2.1B | $2.7B | $2.8B | $3.1B |
| Shareholders' equity | $1.4M | β$347M | β$819M | β$1.1B | β$205M |
| Net debt (β = net cash) | β$319M | $183M | β$572M | β$836M | β$1.7B |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Ptc Therapeutics, Inc. passes 6 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 9 | 3 / 9 | 3 / 9 | 3 / 8 | 2 / 8 | 2 / 8 | 4 / 8 | 3 / 8 | 6 / 8 |
| Accruals ratio | β14.3% | β20.9% | β13.3% | β11.2% | β12.7% | β13.1% | β11.1% | β26.0% | β14.2% | β1.2% |
| Altman Z'' | β6.20 | β4.38 | β2.05 | β0.59 | β0.59 | β3.32 | β5.91 | β5.39 | β5.56 | 1.56 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $82.7M | $194M | $265M | $307M | $381M | $539M | $699M | $938M | $807M | $1.7B |
| Gross profit | $82.7M | $190M | $252M | $295M | β | β | β | β | β | β |
| Research and development | $118M | $117M | $172M | $257M | $478M | $541M | $651M | $667M | $534M | $455M |
| Operating income | β$132M | β$64.3M | β$116M | β$241M | β$432M | β$374M | β$447M | β$440M | β$303M | $867M |
| Pretax income | β$142M | β$77.7M | β$128M | β$240M | β$403M | β$518M | β$587M | β$696M | β$363M | $697M |
| Income tax | $0.6M | $1.3M | β$0.0M | $11.7M | $35.2M | $5.6M | β$28.5M | β$69.5M | $0.2M | $14.0M |
| Net income | β$142M | β$79.0M | β$128M | β$252M | β$438M | β$524M | β$559M | β$627M | β$363M | $683M |
| Net income to common | β | β | β$128M | β$252M | β$438M | β$524M | β$559M | β$627M | β$363M | $683M |
| Diluted EPS | β$4.17 | β$2.02 | β$2.75 | β$4.27 | β$6.64 | β$7.43 | β$7.79 | β$8.37 | β$4.73 | $7.78 |
| Diluted shares | 0.03B | 0.04B | 0.05B | 0.06B | 0.07B | 0.07B | 0.07B | 0.07B | 0.08B | 0.09B |
| Cash flow | ||||||||||
| Cash from operations | β$104M | β$10.1M | β$27.6M | β$98.6M | β$194M | β$251M | β$357M | β$158M | β$108M | $711M |
| Capital expenditure | $1.8M | $3.1M | $7.1M | $13.8M | $17.8M | $28.2M | $32.0M | $28.4M | $6.5M | $8.9M |
| Free cash flow | β$105M | β$13.2M | β$34.7M | β$112M | β$212M | β$280M | β$389M | β$187M | β$114M | $702M |
| Depreciation and amortization | $3.3M | $17.7M | $26.1M | $32.2M | $43.5M | $64.1M | $129M | $237M | $75.7M | $38.8M |
| Stock-based compensation | $35.0M | $30.6M | $33.3M | $42.1M | $70.3M | $104M | $110M | $102M | $74.6M | $74.5M |
| Acquisitions | $0.0M | $0.0M | $48.9M | $0.0M | β | β | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $232M | $191M | $228M | $687M | $1.1B | $773M | $411M | $877M | $1.1B | $1.9B |
| Total debt | $98.2M | $145M | $153M | $314M | $309M | $431M | $572M | $284M | $285M | $287M |
| Finance lease liabilities | β | β | β | $0.0M | $24.3M | $23.1M | $21.7M | $20.2M | $18.6M | $6.0M |
| Current assets | $261M | $249M | $321M | $779M | $1.2B | $954M | $694M | $1.2B | $1.4B | $2.3B |
| Current liabilities | $49.6M | $82.0M | $167M | $236M | $277M | $509M | $406M | $603M | $581M | $968M |
| Inventory | $0.0M | $10.8M | $16.1M | $19.3M | $18.7M | $15.9M | $21.8M | $30.6M | $23.2M | $79.6M |
| Property and equipment, net | $7.4M | $8.4M | $12.7M | $21.5M | $33.8M | $52.6M | $72.6M | $87.1M | $61.0M | $55.4M |
| Goodwill | β | $0.0M | $82.3M | $82.3M | $82.3M | $82.3M | $82.3M | $82.3M | $82.3M | $82.3M |
| Intangible assets | $0.0M | $133M | $701M | $711M | $715M | $725M | $706M | $379M | $119M | $389M |
| Total assets | $269M | $392M | $1.1B | $1.6B | $2.2B | $1.9B | $1.7B | $1.9B | $1.7B | $2.9B |
| Total liabilities | $150M | $235M | $768M | $1.0B | $1.7B | $1.9B | $2.1B | $2.7B | $2.8B | $3.1B |
| Shareholders' equity | $120M | $156M | $351M | $594M | $482M | $1.4M | β$347M | β$819M | β$1.1B | β$205M |
| Margins | ||||||||||
| Gross margin | 100.0% | 97.6% | 95.2% | 96.0% | β | β | β | β | β | β |
| Operating margin | β159.7% | β33.1% | β43.7% | β78.6% | β113.4% | β69.5% | β64.0% | β46.9% | β37.5% | 50.1% |
| EBITDA margin | β155.7% | β24.0% | β33.8% | β68.1% | β102.0% | β57.6% | β45.6% | β21.6% | β28.1% | 52.3% |
| Net margin | β171.8% | β40.6% | β48.4% | β82.0% | β115.1% | β97.3% | β80.0% | β66.8% | β45.0% | 39.4% |
| FCF margin | β127.4% | β6.8% | β13.1% | β36.6% | β55.7% | β51.9% | β55.6% | β19.9% | β14.2% | 40.6% |
| Returns | ||||||||||
| Return on capital | β | β46.1% | β33.1% | β86.0% | β | β | β | β | β | β |
| Return on capital employed | β60.1% | β20.8% | β12.1% | β17.4% | β22.4% | β26.2% | β34.4% | β34.0% | β26.9% | 44.9% |
| Return on equity | β118.8% | β57.2% | β50.5% | β53.2% | β81.4% | β216.7% | β | β | β | β |
| Return on assets | β52.8% | β23.9% | β17.0% | β18.3% | β22.9% | β25.3% | β30.7% | β34.8% | β20.2% | 29.7% |
| Return on tangible equity | β118.8% | β337.0% | β | β | β | β | β | β | β | β |
| Growth | ||||||||||
| Revenue growth | β | 135.0% | 36.2% | 16.0% | 24.0% | 41.4% | 29.7% | 34.2% | β14.0% | 114.5% |
| Share count change | β | 15.1% | 18.9% | 26.4% | 12.2% | 6.7% | 1.8% | 4.3% | 2.7% | 14.9% |
| Financial health | ||||||||||
| Net debt / EBITDA | β | β | β | β | β | β | β | β | β | β1.8x |
| Debt / equity | 0.8x | 0.9x | 0.4x | 0.5x | 0.6x | 300.0x | β | β | β | β |
| Current ratio | 5.3x | 3.0x | 1.9x | 3.3x | 4.4x | 1.9x | 1.7x | 2.0x | 2.4x | 2.3x |
| Quick ratio | 5.3x | 2.9x | 1.8x | 3.2x | 4.4x | 1.8x | 1.7x | 2.0x | 2.3x | 2.3x |
| Capital allocation | ||||||||||
| Capex / revenue | 2.1% | 1.6% | 2.7% | 4.5% | 4.7% | 5.2% | 4.6% | 3.0% | 0.8% | 0.5% |
| Stock comp / revenue | 42.3% | 15.7% | 12.6% | 13.7% | 18.5% | 19.2% | 15.8% | 10.8% | 9.2% | 4.3% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 3.0 | 3.0 | 3.0 | 2.0 | 2.0 | 4.0 | 3.0 | 6.0 |
| Altman Z'' | β6.2 | β4.4 | β2.0 | β0.6 | β0.6 | β3.3 | β5.9 | β5.4 | β5.6 | 1.6 |
| Accruals ratio | β14.3% | β20.9% | β13.3% | β11.2% | β12.7% | β13.1% | β11.1% | β26.0% | β14.2% | β1.2% |
Source: SEC EDGAR XBRL filings (CIK 0001070081). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
